Ultragenyx Pharmaceutical

RARENASDAQ

Rare disease development and commercialization platform spanning biologics, AAV, and small molecules

Drafted with AI assistance from public sources and not individually reviewed by an editor; last updated 2026-04-09. Published by ClinicalInvestor. Educational analysis only. Read the editorial policy and disclosures.

Filing figures as of June 30, 2026 · text updated 2026-04-09, 222 days ago · archived: kept for reference, not maintained · where each field comes from

Key figures from SEC filings

RARE filings on EDGAR →

Cash & investments

$436M

at June 30, 2026 (10-Q)

Quarterly operating burn

$147M

average per quarter, Jan–Jun 2026

Cash runway

~9 months

$436M ÷ $147M per quarter

Shares outstanding

98.6M

cover page of the latest filing

Read from RARE's XBRL financial data; latest filing August 5, 2026; fetched 2026-09-28. Runway assumes the reported burn continues unchanged; burn usually rises as programs advance, so treat it as an upper bound. Revenue stage: Early revenue.

Upcoming catalysts

Company-specific dates below are registry milestones or filings we have linked. For FDA decision dates site-wide, see the PDUFA calendar.

MCE study: Triheptanoin in Long-chain fatty acid oxidation disorders — primary completion

2027-08

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

GTX-301: DTX301 in Late-onset OTC deficiency — primary completion

2027-09

Registry milestone — the date data collection is scheduled to end, not when results are released. ClinicalTrials.gov

Trial milestoneSignificant

Pipeline

DrugIndicationPhaseExpected data
CrysvitaX-linked hypophosphatemiaApprovedNot disclosed▼
UX111Sanfilippo syndrome type APhase 3Not disclosed▼
GTX-102Angelman syndromePhase 2Not disclosed▼

Analysis

We have not yet written an analysis of Ultragenyx Pharmaceutical that is specific and current enough to publish. Earlier text here was removed rather than left up: on most profiles it was a template shared with other companies, and where a correction is listed above, it was written before the facts changed. The filing figures, pipeline and sourced catalysts on this page are current; the written thesis will be added from them.
Trade RARE commission-free on Webullvia Webull · Affiliate

Comparable companies

Sarepta TherapeuticsBioMarin PharmaceuticalAmicus Therapeutics

Sponsored

Get premium RARE analysis on Seeking Alpha

Affiliate link — we may earn a commission at no cost to you

Disclaimer: This page is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell securities. Clinical trial analysis reflects publicly available data and AI-generated interpretations. Biotech investing carries significant risk including potential total loss of investment. Always verify critical claims through primary sources and consult a qualified financial advisor. Some links on this page are affiliate links. Review our editorial policy and disclosures.

Sponsor's late-stage trial record

Ultragenyx Pharmaceutical has 40 Phase 2 or 3 studies on ClinicalTrials.gov: 18 completed, 10 stopped early, 12 ongoing.

18

Completed

10

Stopped early

12

Ongoing

Stopped early

  • NCT05312697Phase 2 · started 2022 · terminated

    Setrusumab in osteogenesis imperfecta · n=2

    Reason given: Sponsor decision not related to safety concerns

  • NCT04990388Phase 1/2 · started 2021 · terminated

    UX053 in glycogen storage disease type iii · n=9

    Reason given: Sponsor decision not related to safety concerns

  • NCT04088734Phase 1/2 · started 2019 · terminated

    ABO-102 in mps iiia · n=5

    Reason given: Terminated due to lack of efficacy seen in patients with advanced MPS IIIA disease. The patients will be followed up annually for safety until five years post dosing

  • MeteoroidPhase 2 · started 2017 · withdrawn

    BPS804 in osteogenesis imperfecta · n=0

    Reason given: Administrative Reason

  • NCT02960217Phase 3 · started 2017 · terminated

    UX007 in glucose transporter type 1 deficiency syndrome (glut1 ds) · n=44

    Reason given: Study was halted prematurely due to lack of efficacy.

  • NCT02736188Phase 3 · started 2016 · terminated

    Aceneuramic Acid Extended-Release Tablets in hereditary inclusion body myopathy · n=143

    No reason recorded in the registry.

  • NCT02731690Phase 2 · started 2016 · terminated

    Aceneuramic Acid Extended-Release in hereditary inclusion body myopathy · n=42

    No reason recorded in the registry.

  • NCT02618915Phase 1/2 · started 2015 · terminated

    DTX101 in hemophilia b · n=6

    Reason given: Sponsor decision; not due to any safety concerns related to DTX101.

  • NCT02599961Phase 2 · started 2015 · terminated

    UX007 in glucose transporter type 1 deficiency syndrome · n=15

    Reason given: Study was halted prematurely due to lack of efficacy

  • NCT01806610Phase 2 · started 2013 · withdrawn

    BPS804 in chronic-kidney disease stage 5d on stable hemodialysis · n=0

    No reason recorded in the registry.

Counts cover interventional Phase 2 and Phase 3 studies registered under this sponsor name, retrieved 2026-09-28 from ClinicalTrials.gov API v2. Trials stop for many reasons — futility, safety, enrollment, funding, or a decision to back a different programme — and the registry often does not say which. This is the sponsor's record, not a prediction about any specific readout.